No Evidence Supports Priming with Apalutamide Before Leuprolide
There is no evidence supporting the practice of "priming" with apalutamide (Erleada) before initiating leuprolide in stage IV prostate cancer. The established treatment paradigm is to start both agents simultaneously, not sequentially.
Standard Treatment Approach
Concurrent Initiation is the Evidence-Based Standard
All major clinical trials and FDA approval for apalutamide in metastatic castration-sensitive prostate cancer (mCSPC) were based on concurrent administration with androgen deprivation therapy (ADT), not sequential priming 1. The TITAN trial, which established apalutamide's efficacy in mCSPC, randomized patients to receive apalutamide 240 mg daily plus ADT versus placebo plus ADT, with both agents started together 2.
ASCO guidelines recommend ADT plus apalutamide as combination therapy for metastatic castration-sensitive disease, with no mention of sequential dosing or priming strategies 3. The FDA label explicitly states that patients should "maintain GnRH analog therapy during the course of treatment with ERLEADA" 1, indicating concurrent use rather than sequential administration.
Why Concurrent Therapy is Superior
Mechanism of Action Supports Simultaneous Use
- Apalutamide blocks androgen receptors while leuprolide suppresses testosterone production
- These complementary mechanisms work synergistically when administered together
- Delaying ADT initiation would allow continued androgen-driven tumor growth during the "priming" period
- The TITAN trial demonstrated significant improvements in radiographic progression-free survival (HR 0.48) and overall survival (HR 0.67) with concurrent therapy 2
Clinical Trial Evidence
The pivotal TITAN study enrolled 1,052 patients with mCSPC who received simultaneous apalutamide plus ADT, achieving:
- 82.4% vs 73.5% overall survival at 24 months
- Median OS not reached vs 52.2 months with extended follow-up
- Consistent benefits across disease volume and Gleason score subgroups 1
Real-world data from 531 patients confirms these findings with concurrent administration, showing 87% achieved PSA90 response and 69% reached PSA ≤0.2 ng/mL 4.
Common Pitfall to Avoid
Do not delay ADT initiation while starting apalutamide. This approach:
- Lacks any supporting evidence
- Contradicts FDA labeling and guideline recommendations
- May allow disease progression during the delay period
- Misunderstands the complementary mechanisms requiring simultaneous blockade
Practical Implementation
When initiating treatment for stage IV prostate cancer:
- Start leuprolide (or other GnRH analog) and apalutamide on the same day or within days of each other
- Apalutamide dosing: 240 mg (four 60 mg tablets) once daily, with or without food 1
- Monitor for adverse events more common with combination therapy: rash (28%), hypothyroidism, and cardiovascular events 2
- Baseline and periodic monitoring: blood pressure, hepatic function, thyroid function, and cardiovascular risk assessment 1
The only scenario where sequential therapy might be considered is in castration-resistant disease, but even then, guidelines do not support priming strategies 3.